Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EPS (Basic) (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EPS (Basic) for 3 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) changed 0.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.06 through Dec 2025, changed 0.0% year-over-year, with the annual reading at -$0.05 for FY2025, 16.67% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.01 at Mereo BioPharma, roughly flat from -$0.01 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.0 in Q2 2023, with the low at -$0.02 in Q1 2023.
  • Average EPS (Basic) over 3 years is -$0.01, with a median of -$0.01 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 50.0% in 2024, while the deepest fall reached 615.23% in 2024.
  • Over 3 years, EPS (Basic) stood at -$0.01 in 2023, then grew by 0.0% to -$0.01 in 2024, then fell by 0.0% to -$0.01 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.01, -$0.01, and -$0.02 for Q4 2025, Q3 2025, and Q2 2025 respectively.